Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR | Market Cap | 99.72B -21.5% |
| Revenue (ttm) | 46.72B +5.5% |
| Net Income | 7.81B +40.5% |
| EPS | 6.37 +43.6% |
| Shares Out | 1.21B |
| PE Ratio | 20.49 |
| Forward PE | 9.77 |
| Dividend | 4.12 (4.97%) |
| Ex-Dividend Date | May 5, 2026 |
| Volume | 1,994,015 |
| Average Volume | 2,817,628 |
| Open | 82.10 |
| Previous Close | 82.87 |
| Day's Range | 81.90 - 83.04 |
| 52-Week Range | 74.85 - 101.90 |
| Beta | 0.36 |
| RSI | 64.72 |
| Earnings Date | Apr 23, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial StatementsNews
Press Release: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease
Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medici...
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
EU regulator backs Sanofi's injectable version of blood cancer drug
French drugmaker Sanofi said on Friday the European Medicines Agency has recommended the approval of a subcutaneous version of its blood cancer drug administered through an on-body injector.
Press release: Availability of the Q1 2026 aide-mémoire
Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026. Sanofi announced today the availability of its Q1 2026 aide-mémoire on the "Investors" page of the company's website: First qua...
Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment
Kali Therapeutics said on Monday it has entered into a licensing agreement with French drugmaker Sanofi to develop the privately held firm's experimental treatment for several autoimmune diseases.
Sanofi launches innovation and operation centre in China
French drugmaker Sanofi launched an innovation and operation centre in the southwestern Chinese city of Chengdu on Thursday, the company said in a statement released on its Chinese social med...
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Mirecule Expands Strategic FSHD Collaboration with Sanofi
GAITHERSBURG, Md.--(BUSINESS WIRE)--Mirecule expands strategic collaboration with Sanofi on advancement of best-in-class ARC treatment of Facioscapulohumeral Muscular Dystrophy (FSHD).
Press Release: Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
Sanofi's venglusta t earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026 . The US Food and Drug Administration (FDA) has granted Breakthrough Therapy des...
Big drugmakers must face US overcharge claims on medications for low-income patients
A U.S. appeals court on Tuesday revived a whistleblower lawsuit accusing four large drugmakers of defrauding the federal and state governments out of hundreds of millions of dollars by overcharging ...
The Big 3: PR, ELF, SNY
From oil, beauty, and therapeutic resource stocks, @ElliottWaveTrader's Tammy Marshall turns to three companies she sees as unsung market opportunities. The Fibonacci Princess offers insight and exa...
Sanofi: An Undervalued Stock For Long-Term Dividend Growth Investors
Sanofi has increased its dividend for 31 consecutive years. That's a fantastic track record. Sanofi increased its revenue from €34.7 billion in FY 2016 to €43.6 billion in FY 2025. That's a compound a...
Sanofi: Information concerning the total number of voting rights and shares - February 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...
Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit
Brazilian drugmaker EMS is open to fresh acquisitions to expand internationally after inking a major deal to buy Sanofi's Brazil-based generic drugmaker Medley, and is gearing up to launch its own se...
Need Growing EPS And Dividends? Prescribe Sanofi
Sanofi is deeply undervalued, trading at a 29% discount to a $65 fair value estimate, with a forward P/E of 9.2 versus a 10-year average of 13. Robust growth is driven by blockbuster drugs like Dupixe...
Press Release: Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director
Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director
Press Release: Filing of an amendment to the French “Document d'Enregistrement Universel” containing the Annual Financial Report
Filing of an amendment to the French “Document d'Enregistrement Universel” containing the Annual Financial Report Paris, March 4, 2026. Sanofi announces today the filing of an amendment to its “Docume...
Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln
Hong Kong-listed Sino Biopharmaceutical said on Wednesday its unit has signed an exclusive global licensing deal with French drugmaker Sanofi worth up to $1.53 billion, giving the European pharma gi...
Press Release: Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RD Third global orphan drug desi...
Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness Recommendation based on phase 2/3 s...
Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition
• Regeneron Pharmaceuticals stock is facing resistance. Why are REGN shares declining?
Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study d...
Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions
Texas Attorney General Ken Paxton on Thursday sued Sanofi for allegedly "bribing" providers to prescribe its medications over alternatives.